Abcuro lands $42m
Abcuro Inc, a developer of therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, has secured $42 million in Series A-1 financing.
Abcuro Inc, a developer of therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, has secured $42 million in Series A-1 financing.
Copyright PEI Media
Not for publication, email or dissemination
